MD3790873T2 - Compuși 1H-indazol-3-carboxamidici în calitate de inhibitori ai glicogensintazkinazei 3-beta - Google Patents
Compuși 1H-indazol-3-carboxamidici în calitate de inhibitori ai glicogensintazkinazei 3-beta Download PDFInfo
- Publication number
- MD3790873T2 MD3790873T2 MDE20210228T MDE20210228T MD3790873T2 MD 3790873 T2 MD3790873 T2 MD 3790873T2 MD E20210228 T MDE20210228 T MD E20210228T MD E20210228 T MDE20210228 T MD E20210228T MD 3790873 T2 MD3790873 T2 MD 3790873T2
- Authority
- MD
- Moldova
- Prior art keywords
- group
- indazole
- alkyl
- mmol
- carboxamide
- Prior art date
Links
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title claims abstract description 73
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title claims abstract description 71
- 150000008581 1H-indazole-3-carboxamides Chemical class 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 208000035475 disorder Diseases 0.000 claims abstract description 29
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 17
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000019022 Mood disease Diseases 0.000 claims abstract description 14
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 11
- 208000004296 neuralgia Diseases 0.000 claims abstract description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 11
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 11
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims abstract description 8
- 208000006029 Cardiomegaly Diseases 0.000 claims abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 8
- 206010015037 epilepsy Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 119
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- -1 1H-Indazole-3-carboxamide compound Chemical class 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000001931 aliphatic group Chemical group 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 12
- 208000020925 Bipolar disease Diseases 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 230000002018 overexpression Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000024714 major depressive disease Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 125000005475 oxolanyl group Chemical group 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 230000002611 ovarian Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 201000009916 Postpartum depression Diseases 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 208000025748 atypical depressive disease Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 3
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 claims description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical group C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 208000009810 Catatonic Schizophrenia Diseases 0.000 claims description 2
- 208000001495 Disorganized Schizophrenia Diseases 0.000 claims description 2
- 208000036755 Schizophrenia simple Diseases 0.000 claims description 2
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 claims description 2
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims description 2
- 208000036750 Schizophrenia, residual type Diseases 0.000 claims description 2
- 206010007776 catatonia Diseases 0.000 claims description 2
- 208000026725 cyclothymic disease Diseases 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 201000003995 melancholia Diseases 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 125000005458 thianyl group Chemical group 0.000 claims description 2
- 125000001166 thiolanyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000020401 Depressive disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 110
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 239000012043 crude product Substances 0.000 description 53
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 36
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 34
- 239000000047 product Substances 0.000 description 34
- 238000003818 flash chromatography Methods 0.000 description 33
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 229910002666 PdCl2 Inorganic materials 0.000 description 28
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 238000000746 purification Methods 0.000 description 25
- 229910004298 SiO 2 Inorganic materials 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 19
- 150000002367 halogens Chemical group 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- AMJVXOOGGBPVCZ-UHFFFAOYSA-N 5-bromo-1h-indazole-3-carboxylic acid Chemical compound C1=C(Br)C=C2C(C(=O)O)=NNC2=C1 AMJVXOOGGBPVCZ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- MKBMOUQSMQVNQW-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carboxamide Chemical compound O1CCC(CC1)CNC(=O)C1=NNC2=CC=C(C=C12)B1OC(C(O1)(C)C)(C)C MKBMOUQSMQVNQW-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- PGBRNRMQNLEWMI-UHFFFAOYSA-N 5-bromo-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 PGBRNRMQNLEWMI-UHFFFAOYSA-N 0.000 description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- SZYXKFKWFYUOGZ-UHFFFAOYSA-N (2,3-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1F SZYXKFKWFYUOGZ-UHFFFAOYSA-N 0.000 description 6
- NOBDKWLIAQKADB-UHFFFAOYSA-N 3-bromopyridine-4-carbaldehyde Chemical compound BrC1=CN=CC=C1C=O NOBDKWLIAQKADB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101150003085 Pdcl gene Proteins 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940102566 valproate Drugs 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- XQHUPBAXLPBXOT-UHFFFAOYSA-N (5-propan-2-yloxypyridin-3-yl)boronic acid Chemical compound CC(C)OC1=CN=CC(B(O)O)=C1 XQHUPBAXLPBXOT-UHFFFAOYSA-N 0.000 description 3
- CMBXJVRGUSEWNE-UHFFFAOYSA-N 3-bromo-5-(methoxymethyl)pyridine Chemical compound COCC1=CN=CC(Br)=C1 CMBXJVRGUSEWNE-UHFFFAOYSA-N 0.000 description 3
- JTXUNXPHKKFQHZ-UHFFFAOYSA-N 5-bromo-N-(1,1-dioxothiolan-3-yl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NC1CS(CC1)(=O)=O JTXUNXPHKKFQHZ-UHFFFAOYSA-N 0.000 description 3
- JEKIULJJFRUMLA-UHFFFAOYSA-N 5-bromo-N-(oxolan-3-ylmethyl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NCC1COCC1 JEKIULJJFRUMLA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 108010001483 Glycogen Synthase Proteins 0.000 description 3
- 101001032567 Homo sapiens Glycogen synthase kinase-3 beta Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LQBUZBOVEZBDEB-UHFFFAOYSA-N (3-bromopyridin-4-yl)methanol Chemical compound OCC1=CC=NC=C1Br LQBUZBOVEZBDEB-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- MNNMTSIVTDNKIF-UHFFFAOYSA-N 1-(3-bromopyridin-4-yl)-N,N-dimethylmethanamine Chemical compound BrC=1C=NC=CC=1CN(C)C MNNMTSIVTDNKIF-UHFFFAOYSA-N 0.000 description 2
- KYVVKZWZFMYZEB-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CN=CC(Br)=C1 KYVVKZWZFMYZEB-UHFFFAOYSA-N 0.000 description 2
- UHDHQYPCHVXIKK-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)-n-methylmethanamine Chemical compound CNCC1=CN=CC(Br)=C1 UHDHQYPCHVXIKK-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000003737 3-Phosphoinositide-Dependent Protein Kinases Human genes 0.000 description 2
- 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 2
- UOVSBUZSLUAARS-UHFFFAOYSA-N 3-bromo-4-(methoxymethyl)pyridine Chemical compound COCC1=CC=NC=C1Br UOVSBUZSLUAARS-UHFFFAOYSA-N 0.000 description 2
- GSELNNMCXHZULG-UHFFFAOYSA-N 3-bromo-4-(pyrrolidin-1-ylmethyl)pyridine Chemical compound BrC1=CN=CC=C1CN1CCCC1 GSELNNMCXHZULG-UHFFFAOYSA-N 0.000 description 2
- UAZLPRVDXABSND-UHFFFAOYSA-N 3-bromo-5-(pyrrolidin-1-ylmethyl)pyridine Chemical compound BrC1=CN=CC(CN2CCCC2)=C1 UAZLPRVDXABSND-UHFFFAOYSA-N 0.000 description 2
- DCOPXKMVVJNPSW-UHFFFAOYSA-N 3-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CN=C1C=O DCOPXKMVVJNPSW-UHFFFAOYSA-N 0.000 description 2
- VKNJQXFLCZNQDL-UHFFFAOYSA-N 4-[(3-bromopyridin-4-yl)methyl]morpholine Chemical compound BrC1=CN=CC=C1CN1CCOCC1 VKNJQXFLCZNQDL-UHFFFAOYSA-N 0.000 description 2
- SUKRVRUMVQCFRL-UHFFFAOYSA-N 4-[(5-bromopyridin-3-yl)methyl]morpholine Chemical compound BrC1=CN=CC(CN2CCOCC2)=C1 SUKRVRUMVQCFRL-UHFFFAOYSA-N 0.000 description 2
- IMKOBBHEFQOPFH-UHFFFAOYSA-N 4-[[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methyl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=CC(CN2CCOCC2)=C1 IMKOBBHEFQOPFH-UHFFFAOYSA-N 0.000 description 2
- RWVVYPCQPAOQAS-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-1H-indazole-3-carboxylic acid Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)O RWVVYPCQPAOQAS-UHFFFAOYSA-N 0.000 description 2
- QIJHQFDCIITVAM-NSHDSACASA-N 5-(2,3-difluorophenyl)-N-[[(3S)-oxolan-3-yl]methyl]-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NC[C@H]1COCC1 QIJHQFDCIITVAM-NSHDSACASA-N 0.000 description 2
- XPAPARXQBNJLPF-UHFFFAOYSA-N 5-bromo-N-(oxan-2-ylmethyl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NCC1OCCCC1 XPAPARXQBNJLPF-UHFFFAOYSA-N 0.000 description 2
- GVEFOWTUDRHIAY-UHFFFAOYSA-N 5-bromo-N-(oxolan-3-yl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NC1COCC1 GVEFOWTUDRHIAY-UHFFFAOYSA-N 0.000 description 2
- RGUNUCKSRKZIRC-UHFFFAOYSA-N 5-bromo-N-[(1,1-dioxothiolan-3-yl)methyl]-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NCC1CS(CC1)(=O)=O RGUNUCKSRKZIRC-UHFFFAOYSA-N 0.000 description 2
- PIIBOBWQWGYERJ-UHFFFAOYSA-N 5-bromo-n-(oxolan-2-ylmethyl)-1h-indazole-3-carboxamide Chemical compound C12=CC(Br)=CC=C2NN=C1C(=O)NCC1CCCO1 PIIBOBWQWGYERJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108091007911 GSKs Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- JDDWRBFSJXTMPT-UHFFFAOYSA-N N-(1,1-dioxothiolan-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carboxamide Chemical compound O=S1(CC(CC1)NC(=O)C1=NNC2=CC=C(C=C12)B1OC(C(O1)(C)C)(C)C)=O JDDWRBFSJXTMPT-UHFFFAOYSA-N 0.000 description 2
- LNNFHZWCVBQASO-UHFFFAOYSA-N N-[(1,1-dioxothiolan-3-yl)methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-3-carboxamide Chemical compound O=S1(CC(CC1)CNC(=O)C1=NNC2=CC=C(C=C12)B1OC(C(O1)(C)C)(C)C)=O LNNFHZWCVBQASO-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 208000025307 bipolar depression Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- RNFBNRPIRRUHQR-UHFFFAOYSA-N methyl 5-(2,3-difluorophenyl)-1H-indazole-3-carboxylate Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)OC RNFBNRPIRRUHQR-UHFFFAOYSA-N 0.000 description 2
- WVNKCZKRGOOMNU-UHFFFAOYSA-N methyl 5-bromo-1h-indazole-3-carboxylate Chemical compound C1=C(Br)C=C2C(C(=O)OC)=NNC2=C1 WVNKCZKRGOOMNU-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- KLLOEDVDDSFXAD-UHFFFAOYSA-N tert-butyl 4-[(3-bromopyridin-4-yl)methyl]piperazine-1-carboxylate Chemical compound BrC=1C=NC=CC=1CN1CCN(CC1)C(=O)OC(C)(C)C KLLOEDVDDSFXAD-UHFFFAOYSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- YCTRDJGHVGMYAO-UHFFFAOYSA-N (1,1-dioxothiolan-3-yl)methanamine Chemical compound NCC1CCS(=O)(=O)C1 YCTRDJGHVGMYAO-UHFFFAOYSA-N 0.000 description 1
- FTTLCYCJDYIEFO-UHFFFAOYSA-N (3-bromopyridin-2-yl)methanol Chemical compound OCC1=NC=CC=C1Br FTTLCYCJDYIEFO-UHFFFAOYSA-N 0.000 description 1
- OVKIDXBGVUQFFC-UHFFFAOYSA-N 1,1-dioxothiolan-3-amine Chemical compound NC1CCS(=O)(=O)C1 OVKIDXBGVUQFFC-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- YMXIIVIQLHYKOT-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical group O1C(C)(C)C(C)(C)OB1C1=CC=CC(N)=C1 YMXIIVIQLHYKOT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LPOOEMSIXFBVLW-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(1,1-dioxothiolan-3-yl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NC1CS(CC1)(=O)=O LPOOEMSIXFBVLW-UHFFFAOYSA-N 0.000 description 1
- NNKGEQQIFGHZTQ-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxan-2-ylmethyl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1OCCCC1 NNKGEQQIFGHZTQ-UHFFFAOYSA-N 0.000 description 1
- CZJASGWYQJACLP-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxan-3-ylmethyl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1COCCC1 CZJASGWYQJACLP-UHFFFAOYSA-N 0.000 description 1
- YBJBHTIPCKIVHE-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 YBJBHTIPCKIVHE-UHFFFAOYSA-N 0.000 description 1
- YCJXPCGLNOBEQG-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxolan-2-ylmethyl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1OCCC1 YCJXPCGLNOBEQG-UHFFFAOYSA-N 0.000 description 1
- NTEXCMYNZMLQIM-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxolan-3-yl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NC1COCC1 NTEXCMYNZMLQIM-UHFFFAOYSA-N 0.000 description 1
- QIJHQFDCIITVAM-UHFFFAOYSA-N 5-(2,3-difluorophenyl)-N-(oxolan-3-ylmethyl)-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1COCC1 QIJHQFDCIITVAM-UHFFFAOYSA-N 0.000 description 1
- QIJHQFDCIITVAM-LLVKDONJSA-N 5-(2,3-difluorophenyl)-N-[[(3R)-oxolan-3-yl]methyl]-1H-indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1F)C=1C=C2C(=NNC2=CC=1)C(=O)NC[C@@H]1COCC1 QIJHQFDCIITVAM-LLVKDONJSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- JIRLCHVAMIDNRT-UHFFFAOYSA-N 5-[4-(hydroxymethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound OCC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 JIRLCHVAMIDNRT-UHFFFAOYSA-N 0.000 description 1
- GTBVWLAMASZLOC-UHFFFAOYSA-N 5-[4-(methoxymethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound COCC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 GTBVWLAMASZLOC-UHFFFAOYSA-N 0.000 description 1
- SGDZWLWSPPYRPJ-UHFFFAOYSA-N 5-[4-(morpholin-4-ylmethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound O1CCN(CC1)CC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 SGDZWLWSPPYRPJ-UHFFFAOYSA-N 0.000 description 1
- DVKDLLRVMDAJHR-UHFFFAOYSA-N 5-[4-[(dimethylamino)methyl]pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound CN(C)CC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 DVKDLLRVMDAJHR-UHFFFAOYSA-N 0.000 description 1
- HMUYSTSHIXJVRO-UHFFFAOYSA-N 5-[5-(hydroxymethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound OCC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 HMUYSTSHIXJVRO-UHFFFAOYSA-N 0.000 description 1
- JWQMLWIDIFDPFG-UHFFFAOYSA-N 5-[5-(methoxymethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound COCC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 JWQMLWIDIFDPFG-UHFFFAOYSA-N 0.000 description 1
- QGJULBKKQCQCPS-UHFFFAOYSA-N 5-[5-(methylaminomethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound CNCC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 QGJULBKKQCQCPS-UHFFFAOYSA-N 0.000 description 1
- MQAYVNMIRZSZOS-UHFFFAOYSA-N 5-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound O1CCN(CC1)CC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 MQAYVNMIRZSZOS-UHFFFAOYSA-N 0.000 description 1
- QJKONXPNNZOALX-UHFFFAOYSA-N 5-[5-[(dimethylamino)methyl]pyridin-3-yl]-N-(oxan-4-ylmethyl)-1H-indazole-3-carboxamide Chemical compound CN(C)CC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 QJKONXPNNZOALX-UHFFFAOYSA-N 0.000 description 1
- PAAMUPRUPDNDTD-UHFFFAOYSA-N 5-bromo-N-(oxan-3-yl)-1H-indazole-3-carboxamide Chemical compound BrC=1C=C2C(=NNC2=CC=1)C(=O)NC1COCCC1 PAAMUPRUPDNDTD-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- OXXGZRNUIYKFTH-UHFFFAOYSA-N N-(1,1-dioxothiolan-3-yl)-5-[5-(hydroxymethyl)pyridin-3-yl]-1H-indazole-3-carboxamide Chemical compound OCC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NC1CS(CC1)(=O)=O OXXGZRNUIYKFTH-UHFFFAOYSA-N 0.000 description 1
- GIGLFCYZHQSMBV-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-(5-propan-2-yloxypyridin-3-yl)-1H-indazole-3-carboxamide Chemical compound C(C)(C)OC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 GIGLFCYZHQSMBV-UHFFFAOYSA-N 0.000 description 1
- MMEHLCAIQOSQRH-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-[4-(piperazin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide Chemical compound N1(CCNCC1)CC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 MMEHLCAIQOSQRH-UHFFFAOYSA-N 0.000 description 1
- NBJILMOOKHDOIC-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-[4-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide Chemical compound N1(CCCC1)CC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 NBJILMOOKHDOIC-UHFFFAOYSA-N 0.000 description 1
- ZXMZFCZQORUDEV-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide Chemical compound N1(CCCC1)CC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 ZXMZFCZQORUDEV-UHFFFAOYSA-N 0.000 description 1
- NOISRBLLEMUOAU-UHFFFAOYSA-N N-(oxan-4-ylmethyl)-5-pyridin-3-yl-1H-indazole-3-carboxamide Chemical compound N1=CC(=CC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1CCOCC1 NOISRBLLEMUOAU-UHFFFAOYSA-N 0.000 description 1
- UOOCVQDYSOPSIJ-UHFFFAOYSA-N N-(oxolan-3-ylmethyl)-5-(5-propan-2-yloxypyridin-3-yl)-1H-indazole-3-carboxamide Chemical compound C(C)(C)OC=1C=C(C=NC=1)C=1C=C2C(=NNC2=CC=1)C(=O)NCC1COCC1 UOOCVQDYSOPSIJ-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- IPEIXQKOAIZNTF-UHFFFAOYSA-N N-tert-butyl-N-(oxan-4-ylmethyl)-5-[4-(piperazin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide Chemical compound N1(CCNCC1)CC1=C(C=NC=C1)C=1C=C2C(=NNC2=CC=1)C(=O)N(CC1CCOCC1)C(C)(C)C IPEIXQKOAIZNTF-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000010566 Potassium Channel Interactions Effects 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002236 anti-hypertrophic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000019711 apoptosis in response to endoplasmic reticulum stress Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- NYGCBQKDTGBHSC-UHFFFAOYSA-N oxan-2-ylmethanamine Chemical compound NCC1CCCCO1 NYGCBQKDTGBHSC-UHFFFAOYSA-N 0.000 description 1
- ZTCHEOLGUZDPAN-UHFFFAOYSA-N oxan-3-ylmethanamine Chemical compound NCC1CCCOC1 ZTCHEOLGUZDPAN-UHFFFAOYSA-N 0.000 description 1
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 1
- YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
- MIPHRQMEIYLZFZ-UHFFFAOYSA-N oxolan-3-amine Chemical compound NC1CCOC1 MIPHRQMEIYLZFZ-UHFFFAOYSA-N 0.000 description 1
- CINJIXGRSTYIHP-UHFFFAOYSA-N oxolan-3-ylmethanamine Chemical compound NCC1CCOC1 CINJIXGRSTYIHP-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006995 pathophysiological pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000006194 pentinyl group Chemical group 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- MFCAGQQYSLKMBZ-UHFFFAOYSA-N tert-butyl 4-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-yl]methyl]piperazine-1-carboxylate Chemical compound CC1(OB(OC1(C)C)C=1C=NC=CC=1CN1CCN(CC1)C(=O)OC(C)(C)C)C MFCAGQQYSLKMBZ-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171084 | 2018-05-07 | ||
| PCT/EP2019/061532 WO2019215075A1 (en) | 2018-05-07 | 2019-05-06 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3790873T2 true MD3790873T2 (ro) | 2022-07-31 |
Family
ID=62134122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210228T MD3790873T2 (ro) | 2018-05-07 | 2019-05-06 | Compuși 1H-indazol-3-carboxamidici în calitate de inhibitori ai glicogensintazkinazei 3-beta |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11472795B2 (https=) |
| EP (1) | EP3790873B1 (https=) |
| JP (1) | JP7411574B2 (https=) |
| KR (1) | KR102778690B1 (https=) |
| CN (1) | CN112135821B (https=) |
| AU (1) | AU2019265606B2 (https=) |
| BR (1) | BR112020021922A2 (https=) |
| CA (1) | CA3094896A1 (https=) |
| CY (1) | CY1125293T1 (https=) |
| DK (1) | DK3790873T3 (https=) |
| EA (1) | EA202092422A1 (https=) |
| ES (1) | ES2913975T3 (https=) |
| GE (2) | GEP20227437B (https=) |
| HR (1) | HRP20220664T1 (https=) |
| HU (1) | HUE058894T2 (https=) |
| IL (1) | IL278330B2 (https=) |
| LT (1) | LT3790873T (https=) |
| MA (1) | MA52557A (https=) |
| MD (1) | MD3790873T2 (https=) |
| MX (1) | MX2020011882A (https=) |
| PL (1) | PL3790873T3 (https=) |
| PT (1) | PT3790873T (https=) |
| RS (1) | RS63255B1 (https=) |
| SG (1) | SG11202009230WA (https=) |
| SI (1) | SI3790873T1 (https=) |
| SM (1) | SMT202200227T1 (https=) |
| UA (1) | UA128089C2 (https=) |
| WO (1) | WO2019215075A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023506257A (ja) * | 2019-12-16 | 2023-02-15 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | 新規なインダゾール誘導体及びその用途 |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| WO2022125377A1 (en) * | 2020-12-08 | 2022-06-16 | Disarm Therapeutics, Inc. | Benzopyrazole inhibitors of sarm1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ257545A (en) | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3473099A1 (en) * | 2011-09-14 | 2019-04-24 | Samumed, LLC | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| CA2860250C (en) * | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| RS54539B1 (sr) | 2012-02-21 | 2016-06-30 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze |
| MX2016012208A (es) * | 2014-03-20 | 2017-01-26 | Samumed Llc | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. |
| AU2019224075A1 (en) * | 2018-02-23 | 2020-09-10 | Samumed, Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-05-06 PT PT197212954T patent/PT3790873T/pt unknown
- 2019-05-06 SG SG11202009230WA patent/SG11202009230WA/en unknown
- 2019-05-06 DK DK19721295.4T patent/DK3790873T3/da active
- 2019-05-06 CN CN201980029405.9A patent/CN112135821B/zh active Active
- 2019-05-06 WO PCT/EP2019/061532 patent/WO2019215075A1/en not_active Ceased
- 2019-05-06 HR HRP20220664TT patent/HRP20220664T1/hr unknown
- 2019-05-06 RS RS20220482A patent/RS63255B1/sr unknown
- 2019-05-06 SI SI201930227T patent/SI3790873T1/sl unknown
- 2019-05-06 IL IL278330A patent/IL278330B2/en unknown
- 2019-05-06 UA UAA202006085A patent/UA128089C2/uk unknown
- 2019-05-06 HU HUE19721295A patent/HUE058894T2/hu unknown
- 2019-05-06 KR KR1020207030163A patent/KR102778690B1/ko active Active
- 2019-05-06 MX MX2020011882A patent/MX2020011882A/es unknown
- 2019-05-06 MD MDE20210228T patent/MD3790873T2/ro unknown
- 2019-05-06 CA CA3094896A patent/CA3094896A1/en active Pending
- 2019-05-06 EP EP19721295.4A patent/EP3790873B1/en active Active
- 2019-05-06 ES ES19721295T patent/ES2913975T3/es active Active
- 2019-05-06 GE GEAP201915506A patent/GEP20227437B/en unknown
- 2019-05-06 LT LTEPPCT/EP2019/061532T patent/LT3790873T/lt unknown
- 2019-05-06 AU AU2019265606A patent/AU2019265606B2/en active Active
- 2019-05-06 GE GEAP202215506A patent/GEAP202215506A/en unknown
- 2019-05-06 MA MA052557A patent/MA52557A/fr unknown
- 2019-05-06 BR BR112020021922-3A patent/BR112020021922A2/pt unknown
- 2019-05-06 EA EA202092422A patent/EA202092422A1/ru unknown
- 2019-05-06 PL PL19721295T patent/PL3790873T3/pl unknown
- 2019-05-06 US US17/051,352 patent/US11472795B2/en active Active
- 2019-05-06 SM SM20220227T patent/SMT202200227T1/it unknown
- 2019-05-06 JP JP2020562568A patent/JP7411574B2/ja active Active
-
2022
- 2022-05-26 CY CY20221100366T patent/CY1125293T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2726115C1 (ru) | Пиридопиримидиновые ингибиторы cdk2/4/6 | |
| CA3232128A1 (en) | Pyridine derivative and use thereof | |
| TW200536849A (en) | Substituted heterocycles and the uses thereof | |
| CA3029097A1 (en) | N-(substituted-phenyl)-sulfonamide derivatives as perk kinase inhibitors | |
| MX2008000574A (es) | Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk. | |
| CA2860466C (en) | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| WO2017156179A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| CA3234750A1 (en) | Modulators of sestrin-gator2 interaction and uses thereof | |
| BR112014018655B1 (pt) | Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica | |
| EP3790873B1 (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| TW202003496A (zh) | 一種新穎磷酸肌醇3 - 激酶抑制劑及其製備方法和用途 | |
| JPWO2006008874A1 (ja) | アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤 | |
| JP2019522682A (ja) | ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用 | |
| CN115697972B (zh) | 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂 | |
| AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| HK40038633A (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| HK40038633B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| CN115703760B (zh) | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 | |
| EA043429B1 (ru) | 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов киназы гликогенсинтазы 3-бета | |
| JP2022546294A (ja) | Ｃｄｃ７阻害剤として使用される四環式化合物 | |
| HK1179171B (en) | Ire-1 inhibitors | |
| HK1179171A (en) | Ire-1 inhibitors |